NY-UNIFRAX
7.4.2021 13:02:12 CEST | Business Wire | Press release
Unifrax , the leading manufacturer of high-performance specialty materials, today introduced a new, nano-structured alumina catalyst support technology for the transportation market – Eco-lytic™ by Unifrax . Housed within a vehicle’s catalytic converter, the Eco-lytic catalyst support fiber is designed to replace the existing catalytic converter or add to existing systems in order to enhance emission reduction, consume fewer precious metals and raw materials, and drive lower energy usage through vehicle weight reduction. The solution is designed to help prolong a cleaner engine life and enable vehicle manufacturers to meet increasingly stringent environmental, social, and governance (ESG) standards and regulations, while providing considerable cost savings as the market transitions to electric vehicles (EVs).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210407005247/en/
Eco-lytic is currently in advanced testing with several global automakers. Preliminary results suggest the solution can reduce the mass of catalyst support media by up to 80 percent and lower platinum group metal loading by up to 40 percent compared to traditional systems. This results in increased efficiency due to faster light-off of catalytic performance. Unifrax will have commercial production capability on-line in late 2021.
“The transportation industry is going through an incredible transformation – vehicle manufacturers and regulators are focusing efforts on reducing greenhouse gas emissions and transitioning to electric or plug-in hybrid vehicles. This transition will not happen overnight, and the industry is in desperate need of nearer-term solutions to help bridge the sector’s transition to a greener footprint. Eco-lytic is that solution and the step change we need today,” said Chad Cannan, Senior Vice President of Research and Development, Unifrax. “Eco-lytic is poised to be a game changer for any conventional engine, large or small, mobile or stationary. Our product is designed to enhance emissions reductions, reduce the need for precious raw materials, extend cleaner engine lives and help drive a more sustainable carbon footprint through vehicle weight reduction.”
Eco-lytic’s flexible structure not only offers efficiency and cost savings benefits, it also provides transportation industry partners and manufacturers with unique packaging options. Unifrax has the ability to tailor the Eco-lytic product to meet the needs of individual partners through custom shapes and sizes to fit into locations where existing technologies cannot.
“Unifrax continues to pursue its mission to make the world a greener, cleaner, and safer place. We have been working to support the industry’s transition to EVs through a robust battery and technology solution portfolio that includes: our recently announced proprietary anode technology SiFab™, which drives significantly higher energy density in lithium ion batteries, our AGM separator materials, our large format lithium ion glass separators, our interstitial thermal runaway barriers, our battery compartment fire protection systems and now Eco-lytic,” said John Dandolph, President and CEO, Unifrax. “Eco-lytic provides an exciting bridge to reduce catalytic converter weights and costs, reduce the use of precious metals and raw materials, and minimize the environmental impact of conventional engines as the industry transitions to EVs. As such, Eco-lytic is a unique and proprietary solution which opens the door to a new age of emission control aligned with our mission at Unifrax.”
Building on Unifrax’s deep history of fiber-based technology and manufacturing, Eco-lytic is Unifrax’s first step into catalytic support. Unifrax, the inventor of specialty ceramic fibers, has a track record of 75+ years of developing and supplying engineered inorganic materials on a large scale to advanced industries worldwide, including electric vehicles, aerospace, and chemical processing.
Unifrax will be available during SAE’s WCX Digital Summit , April 13–15, 2021, to discuss the Eco-lytic technology with interested attendees. For more information on Eco-lytic, visit www.unifrax.com .
About Unifrax
Unifrax develops and manufactures high performance specialty materials used in advanced applications including high-temperature industrial insulation, electric vehicles, energy storage, filtration, and fire protection, among many others. Unifrax products are designed with the ultimate goal of saving energy, reducing pollution, and improving safety for people, buildings and equipment by delivering on our commitment to our customers of greener, cleaner, safer solutions for their application challenges. Unifrax has 37 manufacturing facilities operating in 12 countries and employs 2,700+ employees globally. More information is available at www.unifrax.com . For updates, follow us on Twitter , LinkedIn , and Facebook .
About Clearlake
Founded in 2006, Clearlake Capital Group, L.P. is an investment firm operating integrated businesses across private equity, credit and other related strategies. With a sector-focused approach, the firm seeks to partner with experienced management teams by providing patient, long term capital to dynamic businesses that can benefit from Clearlake’s operational improvement approach, O.P.S.® The firm’s core target sectors are industrials, technology, and consumer. Clearlake currently has approximately $35 billion of assets under management, and its senior investment principals have led or co-led over 300 investments. The firm has offices in Santa Monica and Dallas. More information is available at www.clearlake.com and on Twitter @ClearlakeCap .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210407005247/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
